Interim Results

RNS Number : 3875M
Versarien PLC
21 January 2021
 

 

21 January 2021

 

Versarien Plc

 

("Versarien", the "Company" or the "Group")

 

Interim Results for the six months ended 30 September 2020

 

Versarien Plc (AIM: VRS), the advanced engineering materials group, is pleased to announce its interim results for the six months ended 30 September 2020, a period in which the Company continued to progress its graphene commercialisation strategy.

 

Financial Highlights

 

· Group revenues reduced to £3.12 million (H1 2019: £4.38 million), reflecting the impact of COVID-19 on the Group's more mature businesses

· Graphene and graphene product sales of £0.35 million (H1 2019: £0.07 million)

· Adjusted LBITDA* of £1.13 million (H1 2019: £0.57 million**)

· Reported loss before tax of £4.34 million (H1 2019: £2.14 million)

· Cash of £2.50 million at 30 September 2020 (31 March 2020: £1.66 million)

·     Cash received in the period from Lanstead Sharing Agreement of £0.93 million and from Innovate UK of £1.96 million

 

*Adjusted LBITDA (Loss Before Interest, Tax, Depreciation and Amortisation) excludes exceptional items, share-based payment charges and other gains/losses)

** The comparative has been restated in accordance with the adoption of IFRS 16 "Leases"

 

Operational Highlights

 

· Successful launch of graphene enhanced protective face masks utilising PolygreneTM, Versarien's graphene enhanced polymer

· Awarded £5 million Innovate UK loan with first tranche of £1.96 million received for the Company's GSCALE project

· Project commenced with Rolls Royce and the Graphene Engineering Innovation Centre to understand and create technological advances in the aerospace sector utilising CVD graphene and other 2D materials

· Commencement of project with the Advanced Propulsion Centre for reduction of vehicle emissions

· Formation of the Versarien Graphene Advisory Panel ("VGAP")

· Board strengthened by the appointment of James Stewart as the Company's new independent Non-executive Chairman

 

GSCALE Highlights

 

· G - Trials ongoing to achieve capacity greater than 10 tonnes of graphene powder per annum

· S - Working with partners to develop rail carriage door side panels; phase 3 tests underway with aerospace partners

· C - GraphinksTM in concrete has demonstrated an almost 40% improvement to the compressive strength and 25% increased resistivity

· A - Infrastructure bridging solutions in course of development using knowledge gained from rail arch

· L - GrapheneWearTM   base layers produced and in course of distribution for wearer trials

· E - Graphene in tyres shows a 30% increase in tyre rubber stiffness without degrading wear resistance

 

Post Period Highlights

 

· Independent report by Ankara University confirming that Versarien's graphene materials significantly inhibit viral infection and possess anti-viral activity towards SARS-CoV-2 coronavirus

· Second generation graphene enhanced face mask prototype test results show a 99.92% anti-viral activity rate against the SARS-CoV-2 virus

· Awarded a £1.95 million development agreement by the Defence, Science and Technology Laboratory, a part of the Ministry of Defence

· Acquisition of CVD graphene assets and IP from Hanwha Aerospace Company Limited, South Korea, supported by the second Lanstead subscription and Sharing Agreement

· Award of EU Grant of €357,000 to Gnanomat for scale-up and development of electrode materials

· Appointment of Steve Hodge to the Company's Board as Chief Technology Officer

 

Neill Ricketts, CEO of Versarien, commented:

 

"Despite the challenges posed by the COVID-19 pandemic, I am pleased with the level at which Versarien has continued to operate and particularly with the progress achieved within the graphene businesses where we have commenced the sale of our graphene enhanced face masks, as well as making further progress with a number of our collaborative projects.

 

"Following the launch of our face masks, we are excited that testing carried out by Ankara University has demonstrated that our hybrid graphene nanomaterials have the potential to provide protection from COVID-19 in real-world applications, including clothing and surface treatments. Prototypes for the second generation face masks have also been tested against SARS-CoV-2 and demonstrated a 99.92% resistance to the virus.

 

"With the acquisition of the CVD assets and IP from Hanwha Aerospace, South Korea, we now have a broad portfolio of graphene products and technologies that can service the addressable market available to us, particularly in Asia, and we intend to fully capitalise on these and other opportunities, such as our GSCALE collaborations, in the year ahead.

 

"In addition, we were delighted to announce the formation of the VGAP, which, thanks to the calibre of its members will play a key role in advancing our strategy to commercialise the many opportunities and applications we have. The panel will provide a platform for the debate and advancement of our graphene technology and its application both for the present and the future.

 

"We continue to be greatly appreciative of the support the UK Government has shown Versarien and its subsidiaries and, as such, we are proud to have provided essential supplies for the NHS and UK infrastructure at this crucial time. The employees in our businesses have been both flexible and supportive during these difficult times and it is their dedication which continues to facilitate our progress.

 

"Test results from the GSCALE projects have been extremely encouraging with highlights including almost 40% improvement in compressive strength in concrete and a 30% increase in tyre rubber stiffness without degrading wear resistance.

 

"We remain both determined and confident in meeting our objective of being the leading global graphene technology business and we look forward to making significant further commercial progress in 2021."

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

 

 

For further information please contact:

 

Versarien Plc

 

Neill Ricketts - Chief Executive Officer

+44 (0) 1242 269122

Chris Leigh - Chief Financial Officer

 

 

 

SP Angel Corporate Finance (Nominated Adviser and Joint Broker)

 

Matthew Johnson

Ewan Leggat

Adam Cowl

+44 (0) 20 3470 0470

 

 

Berenberg (Joint Broker)

 

Mark Whitmore

Simon Cardron

+44 (0) 20 3207 7800

 

 

Yellow Jersey (Investor Relations) 

Versarien@yellowjersey.pr.com

Charles Goodwin

Georgia Colkin

Henry Wilkinson

+44 (0) 20 3004 9512

 

 

Notes to Editors:

 

Versarien Plc ( AIM:VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries.

 

For further information please see:   http://www.versarien.com  

 

 

Chairman's Statement

 

In my first statement in the 2020 Annual Report, following my appointment in June 2020, I was pleased to highlight the progress the Company had made in the year then ended, as well as beyond, and also on its strategic focus on monetisation of the Company's graphene technology.

 

In particular, reference was made to the support of the UK Government which has continued with the £1.95 million development agreement awarded in November 2020. Government support is an important pillar of our strategy as we continue to lay the foundations for our international expansion.

 

The acquisition of the CVD assets and IP from Hanwha Aerospace Company Limited ("Hanwha") is an important step in ensuring that we have an appropriate portfolio of graphene products and technologies that can service the addressable market opportunities in front of us, particularly in Asia. Versarien Korea Limited has been formed as a subsidiary and will be the initial platform for commercialising opportunities in South Korea.

 

Our wholly owned subsidiary Beijing Versarien Technology Company Limited ("BVT") in China has been working with the graphene mask supplier on a number of variants which are now available for supply. BVT continues to work with companies that fall within the GSCALE project such as those operating in the concrete and textile sectors. 

 

Furthermore, I am pleased to report the Company has continued to operate all its businesses and progress its graphene commercialisation strategy in these difficult times, together with providing essential supplies for the NHS and UK infrastructure. We are utilising the UK Government furlough scheme where required, homeworking has been implemented where appropriate and those at work operate in accordance with the COVID-19 safety guidelines.

 

I would like to thank all our staff for their continued endeavours without which we would not have been able to make the progress that we have. Furthermore, I am delighted that Steve Hodge's commitment has been recognised by his recent appointment to the Board as Chief Technology Officer. I am confident that we have the executive team to deliver graphene commercialisation.

 

 

James Stewart CBE

Non-executive Chairman

21 January 2021

 

 

 

 

Chief Executive Officer's Review

 

Our 2020 Annual Report laid out the steps for executing our graphene commercialisation strategy including access to high quality facilities such as the University of Manchester based Graphene Engineering Innovation Centre ("GEIC"), expanding our patent portfolio, ensuring that we have appropriate investment in place and achieving commercial progress. I believe that during the period under review and more recently we have made significant advancement in these areas.

 

Acquisition of graphene assets and intellectual property from Hanwha

 

I am particularly pleased that we have, post period end, been able to close the transaction with Hanwha in South Korea to acquire its chemical vapour deposition ("CVD") graphene assets and IP. The acquisition will provide us with access to patented technology and equipment to produce high quality single and dual layer graphene that has particular applications in the electronics sector, together with other areas, including in relation to some of our existing collaborations, particularly the project with Rolls Royce.

 

Based on information provided by Hanwha as part of the sale process:

 

· Its graphene business started in 2009 with a project to develop technologies for graphene synthesis and in 2010 the SKKU Samsung Graphene Centre was established. It succeeded in synthesising 30-inch graphene for the first time. In 2011 the South Korean Ministry of Trade, Industry and Energy ("MOTIE") launched the Industry Source Technology Development Project (entitled "Development of transfer and continuous manufacturing technology for flexible nano film") to build a system for processing large-scale films (500mm-level) and a pilot line was built to produce 15-inch graphene film for transparent electrodes. In 2013 prototype graphene-based touch panels were produced for cellphones. 

 

· The same year MOTIE launched a project for the commercialisation of technology for the synthesis of ultrathin graphene layers and graphene-based flexible touch panels which was completed in 2019. The objective was to develop and commercialise graphene-based transparent electrodes for touch panels thereby substituting Indium Tin Oxide.    

 

· In 2015, the South Korean Ministry of Science and ICT ("MSIT") launched a project for the development of equipment and techniques for non-destructive quality evaluation of large-area graphene which was completed in September 2020.

 

· These and other projects have resulted in a total of over 100 patents and patent rights regarding CVD graphene in Korea, the US, China and Japan and which include synthesis, etching, transfer and application technology. Addressable markets for this technology include flexible touch panels, electrochromic heating, OLED lighting and heating films for electric vehicles.  

 

The assets were acquired for a consideration of 11 million Versarien Ordinary Shares which at the time of issue represented a market value of £4.3 million. As part of the due diligence, the equipment was independently valued at £0.85 million with an estimated replacement cost of £2.2 million. The value of the patent portfolio continues to be assessed, both in terms of its revenue generating opportunities from development and manufacture and in terms of potential royalties from licensing agreements where blocking patents may exist.

 

Completion of the patent transfer process is in progress and we are evaluating premises options for the plant and equipment whilst also being in discussions locally for the establishment of operations and staffing under the umbrella of our newly formed wholly owned subsidiary incorporated in South Korea, Versarien Korea Limited.

 

GSCALE Project

 

The GSCALE (an acronym for Graphene, Seat, Concrete, Arch, Leisure, Elastomer) project, which is designed to enable Versarien to significantly increase its manufacture of quality assured graphene, is progressing and I am pleased to provide the following update:

 

Work Package G (Graphene)

 

This work package will enable us to scale up capacity for production to greater than 10 tonnes of graphene powder per year. We are developing new and improved processing techniques, and developing and commissioning reliable in-process tests. For the Graphinks TM process, computational fluid dynamics ("CFD") modelling has been performed on newly designed microchannels. Complementary experimental work has been performed using pilot scale rental homogenizers and samples are being analysed prior to a decision on system purchase.

 

We are in discussions with our raw material additive manufacturer regarding scale up and recycling. Trials are ongoing with our equipment manufacturer overseas to investigate graphene scale up using larger processing systems.

 

Our newly appointed CTO, Steve Hodge, has become Chairman of the Graphene REACH Registration Consortium Technical Working Group (TWG) and is a representative of Graphene Flagship's ECHA-REACH Committee.

 

The European Chemicals Agency (ECHA) has recently accepted an updated graphene-dossier that now complies with the amended REACH regulation covering nanomaterials, introduced on 1 January 2020. Our REACH registration has also now been transferred to UK-REACH following Brexit.

 

Work Package S (Seat)

 

This work package will enable us to develop a dispersion facility at our factory in Cheltenham involving the dispersion of graphene in various thermoset systems used in fibre reinforced polymer composites.

 

We are working with partners to develop graphene-enhanced composites for rail interior applications, including a demonstrator for a rail carriage door side panel. Phase 3 tests are underway with aerospace supply chain partners for graphene enhanced composites.

 

We have continued to widen our knowledge base and have demonstrated ~5% improvement in tensile modulus of even the stiffest pitch CFRP composites. We are also looking towards bio-derived composite systems that cannot yet compete mechanically with traditional epoxy systems and have seen 20% improvements in mechanical performance using our NaneneTM in bio-prepreg based composites.

 

Work Package C (Concrete)

 

This work package involves the use of graphene in a number of construction related projects with the key objective of working towards 'Net Zero Carbon' targets. Graphene enhanced concrete could reduce the quantity of cement used in structures as well as the volume of aggregates and as such lead to significant CO2 footprint savings. Graphene brings improvements to the compressive strength of the material and durability, improvement to water permeability and thermal properties to improve speed of construction. These benefits could also reduce the need for expensive chemical additives or specialist material coatings. 

 

So far, our use of GraphinksTM in concrete has demonstrated an almost 40% improvement to the compressive strength and 25% increased resistivity from the base material. A higher resistivity can help prevent electrolytic corrosion of reinforcement steel bars used in large concrete structures; combined with improved resistance to water permeability that we have also witnessed, this could significantly increase the life of the concrete and the asset. We are now working towards a number of field demonstrators in 2021 with several key partners.

 

We are also part of the ACORN initiative whose primary objective is to drive acceptance of a new culture in the construction industry that embraces the concept of using enough material and no more, in order to enhance sector-wide sustainability and productivity.

 

Work Package A (Arch)

 

This work package involves the use of graphene in a number of thermoplastic composite related projects. The aim is to use the knowledge gained in 3D printed graphene for various uses including technology infrastructure and footbridges.

 

The next step for this programme is to develop bridging solutions which will be aided by our new SME Affiliate member status with the National Composites Centre ("NCC"). The 3D printed polymer solutions (Additive Manufacturing) will focus on the rail industry safety and cost awareness by creating lightweight structures that can be installed in a safer and quicker manner, thus also reducing the time of costly line closures.

 

Work Package L (Leisure)

 

This work package covers integrating graphene into textiles, as both a coating and integrated as part of filaments and yarns.

 

Relating to coatings, our objective is to solidify in-house know-how on the formulations of GraphinksTM already developed, to complete ongoing tests for graphene enhanced textiles (anti-viral, anti-bacterial, anti-odour properties) for personal protective equipment (PPE) and sportswear products. W e have commenced trademarking GrapheneWearTM and have a range of base-layers that were launched in late 2020, produced by MAS Innovate (Private) Limited ("MAS"), Sri Lanka. Samples will be distributed shortly to a number of end customers for testing.

 

Relating to textile yarns, the aim is to develop quality control/assurance procedures and the commercialisation of PolygreneTM compounds and masterbatches in a range of polymers including polypropylenes, polyesters and polyamides/nylons. So far we have achieved commercialisation of graphene face masks utilising PolygreneTM, and we have converted PolygreneTM polypropylene masterbatches to non-woven mats and chopped fibres on a pilot scale. We also have pilot scale polyester monofilament fibre-spinning trials ongoing following successful compound development in collaboration with Warwick Manufacturing Group ("WMG").

 

Overall, we have solidified and extended our global supply chain partners (formulators, converters and end customers) that now includes Coats Group PLC, in addition to MAS.

 

Work Package E (Elastomers)

 

This work package aims to develop large-scale graphene-enhanced elastomer masterbatches. Initially this was for two key sectors, oil & gas and automotive tyres, but has been expanded to other sectors including shoes where we continue to develop and optimise sole formulations for a well-known end customer.

 

In oil & gas we have produced an 80 kg graphene/rubber masterbatch to support large scale compounding trials at a customer site in the US. In tyres, initial tests which have been undertaken indicate that we can increase the modulus (stiffness) of the tyre rubber compound by 30%. This increase in stiffness is achieved with no increase in tyre hardness which means that while rolling resistance is decreased, there is no loss of grip that would be associated with a harder tyre. If these results can be maintained or even improved at scale up, this project could lead to the production of tyres specifically aimed at the electric vehicle market.

 

Other Projects

 

The award of the product development agreement for £1.95 million by the Defence, Science and Technology Laboratory ("DSTL"), a part of the Ministry of Defence, in November 2020, demonstrates the support we are receiving from UK Government and acknowledges the quality of our products and technical ability. The agreement involves developing graphene loaded polymer composites for certain defence related applications and is due for completion by 31 March 2022.

 

The collaboration with Rolls Royce and the GEIC to investigate the growth of CVD grown graphene on copper wires is ongoing. The surface of copper wires is an oxide rich region, that plays no part in electrical conduction and which becomes significant as the wire gauge gets smaller and smaller. Graphene enables the copper surface to remain oxide-free after the growth process, allowing for reduced weight and higher current-carrying capacity.

 

Significant progress has been made optimising growth conditions for uniform multi-layer graphene on copper wires in a batch process. High temperature exposure leads to excessive oxidation of copper, however, minimal oxidation to graphene coated copper wires is observed when quantitatively assessed by Raman spectroscopy that can monitor the presence of both graphene and copper oxide peaks simultaneously. Two and four point DC resistivity measurements have shown early indications of reduced contact resistances for graphene coated copper wires, a sign that graphene could offer great potential in the design of future aircraft.

 

Despite the difficult US climate, we continue to work on opportunities in the US including masks, products for a leading manufacturer of premium consumer/industrial paint for coatings and tyres.

 

In Spain, Gnanomat has continued to make progress and has been awarded a €357,000 grant by the European Union ("EU"). This funding forms part of a total grant of over €14 million awarded to INN-PRESSME, a consortium project of which Gnanomat is a member.

 

Through this grant and project, Gnanomat will acquire and integrate new industrial equipment into the existing pilot plant and be involved in the development of electrode materials for supercapacitors, in collaboration with industrial partners such as CIDETEC and Skeleton Technologies, who are both involved in the development of energy storage technologies.

Additionally, Gnanomat nanomaterials are currently being tested with leading supercapacitor companies and have shown excellent functionality as a catalyst in energy storage systems such as metal/air batteries resulting in the company filing a new patent application. It has also launched a commercial channel to provide advance material products at small scale for R&D purposes.

Gnanomat's technology has also been key to producing the graphene nanoplatelet batches doped with different metal oxide nanoparticles utilised in the testing by Ankara University to ascertain whether these materials can inactivate the SARS-CoV-2 coronavirus.

In China, work has been ongoing with our partner producing graphene enhanced face masks and we are now able to supply coloured adult masks and children's masks. Testing of a second generation graphene enhanced face mask prototype has been conducted in China at the Analytical and Testing Centre of Capital Regions ("ATCCR") and the test results recently received show a 99.92% anti-viral activity rate against the SARS-CoV-2 virus.

 

VGAP

 

I am delighted with the composition of the Versarien Graphene Advisory Panel ("VGAP") which brings together some of the most eminent and knowledgeable people in the graphene sector. It is chaired by our Non-executive Director, Professor Iain Gray and includes James Baker (CEO of Graphene @Manchester), Dr. Branson Belle (senior scientist at SINTEF Norway), Professor Andrea Ferrari (Founded and directs the Cambridge Graphene Centre), Dr Kari Hjelt (The Graphene Flagships' Head of Innovation), Professor Tony McNally (Head of Nanocomposites Research at the Warwick Manufacturing Group) and Jacqui Murray (Deputy director of the Faraday Battery Challenge).

 

The formation of the VGAP and the calibre of its members is key to advancing our strategy to commercialise the many opportunities and applications we have. It will also provide a platform for the debate and advancement of our graphene technology and its application both for the present and the future.

 

Mature businesses

 

The mature businesses have experienced lower revenues as a result of the pandemic, but have remained operational whilst keeping strict control of costs and using the Government furlough scheme where appropriate.

 

Current trading and outlook

 

The latest national lockdown will continue to create a challenging environment for our more mature businesses. However, the opportunities afforded by GSCALE, the DSTL development agreement and South Korean CVD graphene assets, together with the many collaboration agreements provide the opportunities to pursue our goal of graphene commercialisation both in the UK and abroad.

 

We remain both determined and confident in meeting our objective of being the leading global graphene technology business and we look forward to making further significant commercial progress in 2021.

 

 

 

Neill Ricketts

Chief Executive Officer

21 January 2021

 

Chief Financial Officer's review

 

Group Results

 

Versarien's revenue for the six months ended 30 September 2020 was £3.12 million (H1 2019: £4.38 million), down by £1.26 million as the effects of the pandemic impacted our customer base in the mature businesses in both business segments. However, sales of graphene enhanced masks added an additional £0.33 million of revenues in H1 2020.

 

The loss from operations was £4.28 million (H1 2019: £2.06 million). This was after charging £1.82 million in respect of the six-monthly valuation of the first Lanstead Sharing Agreement, which if valued as of 19 January 2021 would be a charge of £15,000. Due to the nature of the agreement, the balance sheet valuation is sensitive to movement in the Company's share price.

 

The adjusted LBITDA for the period is calculated as follows:

 

 

Six months ended

30 September 2020

£'000

Restated Six months ended

30 September 2019

£'000

Loss from operations 

(4,275)

(2,060)

Depreciation and Amortisation

552

564

Share based payments

597

596

Exceptional items

178

327

Other gains/(losses)

1,817

-

Adjusted LBITDA

(1,131)

(573)

 

Exceptional costs were incurred in the period of £0.18 million (2019: £0.33 million), which mostly relate to the costs incurred for expansion into China and the acquisition of the CVD graphene assets from Hanwha. The reported loss before tax for the period was £4.34 million (H1 2019: £2.14 million).

 

Group net assets at 30 September 2020 were £11.92 million (31 March 2020: £15.66 million), with cash at the period end of £2.51 million (31 March 2020: £1.66 million). Cash outflow from operating activities was £0.68 million (H1 2020: £0.76 million). The Group capitalised £0.17 million (H1 2019: £0.17 million) in development costs during the period.

 

As a result of careful working capital management total cash outflow for the period (being net cash used in operating activities, net cash used in investing activities and principal payment of leases under IFRS 16) totalled £1.4 million; an average of £233,000 per month. During the period four instalments of the Lanstead Sharing Agreement were received totalling £925,000; an average of £231,000 per month which enabled us to preserve our operating cash position as the Sharing Agreement proceeds are received. The monthly proceeds from the Sharing Agreement are based upon the 20-day volume weighted average price ("VWAP)" of Versarien's share price which during the period was below the average benchmark price. As at 20 January 2021 the share price is above the benchmark price of 53.33 pence.

 

Graphene and Plastic Products

 

This segment generated revenue, predominantly from the plastics business, of £1.69 million (H1 2019: £1.85 million), returning an LBITDA before exceptional items, of £0.73 million (H1 2019: adjusted loss £0.77 million). The segment capitalised development costs of £0.13 million (H1 2019: £0.15 million) as work continued on developing specific applications using graphene. Cash used by the business segment was £1.19 million.

 

Hard Wear and Metallic Products

 

Revenue for the period was £1.43 million (H1 2019: £2.52 million), with an EBITDA before exceptional items of £0.05 million (H1 2019: adjusted £0.53 million). The segment used £0.06 million in cash in the period.

 

 

Chris Leigh

Chief Financial Officer

21 January 2021

 

 Consolidated Interim Financial Statements

 

Group statement of comprehensive income

For the half year ended 30 September 2020

 

 

Notes

Six months ended

30 September

2020

Unaudited

£'000

Restated *

Six months ended

30 September

2019

Unaudited

£'000

Continuing operations

 

 

 

Revenue

2

3,117

4,376

Cost of sales

 

(2,607)

(3,157)

Gross profit

 

510

1,219

Other operating income

 

74

3

Other gains/(losses)

 

(1,817)

-

Operating expenses (including exceptional items)

 

(3,042)

(3,282)

Loss from operations before exceptional items

 

(4,097)

(1,733)

Exceptional items

3

(178)

(327)

Loss from operations

 

(4,275)

(2,060)

Finance charge

 

(64)

(77)

Loss before income tax

 

(4,339)

(2,137)

Income tax

4

-

-

Loss for the period

 

(4,339)

(2,137)

Loss attributable to:

 

 

 

- Owners of the parent company

 

(4,158)

(1,878)

- Non-controlling interest

 

(181)

(259)

 

 

(4,339)

(2,137)

Loss per share attributable to the equity holders of the Company:

 

 

 

Basic and diluted loss per share

5

(2.45)p

(1.22)p

 

There were no comprehensive gains or losses in the year other than those included in the Group Statement of Comprehensive Income.

 

The other losses in the period relates to the fair value assessment of the Lanstead Sharing Agreement at the balance sheet date.

 

* The prior period results have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases', see note 8 for further information

 

Group statement of financial position

As at 30 September 2020

 

 

Note

30 September

2020

Unaudited

£'000

31 March

2020

Audited

£'000

Assets

 

 

 

Non-current assets

 

 

 

Intangible Assets

6

4,842

4,720

Property, plant and equipment

 

3,808

4,316

Deferred taxation

 

25

25

Trade and other receivables

 

1,553

4,295

 

 

10,228

13,356

Current assets

 

 

 

Inventory

 

2,010

2,252

Trade and other receivables

 

4,429

4,817

Current tax

 

98

157

Cash and cash equivalents

 

2,506

1,657

 

 

9,043

8,883

Total assets

 

19,271

22,239

Equity

 

 

 

Called up share capital

 

1,697

1,697

Share premium

 

25,497

25,497

Merger reserve

 

1,256

1,256

Share-based payment reserve

 

2,653

2,056

Accumulated losses

 

(18,004)

(13,846)

Equity attributable to owners of the parent company

 

13,099

16,660

Non-controlling interest

 

(1,180)

(999)

Total equity

 

11,919

15,661

Liabilities

 

 

 

Non-current liabilities

 

 

 

Trade and other payables

 

  2,941

  1,192

Deferred taxation

 

67

67

Long-term borrowings

 

376

516

 

 

3,384

1,775

Current liabilities

 

 

 

Trade and other payables

 

2,447

2,928

Provisions

 

97

97

Current tax

 

617

290

Invoice discounting advances

 

513

1,156

Current portion of long-term borrowings

 

294

332

 

 

3,968

4,803

Total liabilities

 

7,352

6,578

Total equity and liabilities

 

19,271

22,239

 

Group statement of changes in equity

For the half year ended 30 September 2020

 

 

Share

capital

£'000

Share

premium

account

£'000

Merger

reserve

£'000

Share-based

payment

reserve

£'000

Accumulated

losses

£'000

Non-

controlling

interest

£'000

Total

equity

£'000

At 1 April 2019 (audited)

1,536

19,776

  1,256

899

(9,698)

(493)

13,276

Issue of shares, net of issue costs

3

120

-

-

-

-

123

Loss for the period (restated *)

-

-

-

-

(1,878)

(259)

(2,137)

Share-based charge

-

-

-

596

-

-

596

At 30 September 2019 (unaudited)

1,539

19,896

  1,256

1,495

(11,576)

(752)

11,858

Issue of shares

158

5,601

-

-

-

-

5,759

Loss for the period

-

-

-

-

(2,270)

(247)

(2,517)

Share-based payments

-

-

-

561

-

-

561

At 31 March 2020 (audited)

1,697

25,497

  1,256

2,056

(13,846)

(999)

15,661

Loss for the period

-

-

-

-

(4,158)

(181)

(4,339)

Share-based payments

-

-

-

597

-

-

597

At 30 September 2020 (unaudited)

1,697

25,497

1,256

2,653

(18,004)

(1,180)

11,919

 

Included within the merger reserve is £53,000 in respect of the merger with Versarien Technologies Limited and £964,000 in respect of the acquisition of Total Carbide Limited and £239,000 in respect of the acquisition of AAC Cyroma Limited.

 

* The prior period results have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases', see note 8 for further information

 

Statement of Group cash flows

For the half year ended 30 September 2020

 

 

Six months ended

30 September

2020

Unaudited

£'000

Restated*

Six months ended

30 September

2019

Unaudited

£'000

Cash flows from operating activities

 

 

Cash used in operations

(683)

(764)

Interest paid

(64)

(77)

Net cash used in operating activities

(747)

(841)

Cash flows from investing activities

 

 

Purchase of intangible assets

(169)

(165)

Purchase of property, plant and equipment

(1)

(126)

Net cash used in investing activities

(170)

(291)

Cash flows from financing activities

 

 

Share issue

-

123

Principal payment of leases under IFRS 16

(480)

(456)

Innovate UK loan received

1,964

-

Funds received from Lanstead Sharing Agreement

925

-

Invoice discounting advances

(643)

(187)

Net cash generated from financing activities

1,766

(520)

Increase/(decrease) in cash and cash equivalents

849

(1,652)

Cash and cash equivalents at start of period

1,657

4,292

Cash and cash equivalents at end of period

2,506

2,640

 

 

* The prior period results have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases', see note 8 for further information

 

Note to the statement of Group cash flows

For the half year ended 30 September   2020

 

 

Six months ended

30 September

2020

Unaudited

£'000

Restated*

Six months ended

30 September

2019

Unaudited

£'000

Loss before income tax

(4,339)

(2,137)

Adjustments for:

 

 

Share-based payments

597

596

Depreciation and amortisation

552

564

Disposal of non-current assets

4

-

Finance cost

64

77

Loss on FV movement of share agreement

1,817

-

Decrease/(Increase) in inventories

242

(7)

Decrease in trade and other receivables

447

125

Increase/(decrease) in trade and other payables

(67)

18

Cash used in operations

(683)

(764)

 

 

* The prior period results have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases', see note 8 for further information

 

Notes to the unaudited interim statements

For the half year ended 30 September 2020

 

1. Basis of preparation

Versarien Plc is an AIM quoted company incorporated and domiciled in the United Kingdom under the Companies Act 2006. The Company's registered office and its principal place of business is 2 Chosen View Road, Cheltenham, Gloucestershire, GL51 9LT.

The interim financial statements were prepared by the Directors and approved for issue on 21 January 2021. These interim financial statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2020 were approved by the Board of Directors on 10 September 2020 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified and did not contain statements under sections 498 (2) or (3) of the Companies Act 2006.

As permitted, these interim financial statements have been prepared in accordance with UK AIM Rules and IAS 34, " Interim Financial Reporting" as adopted by the European Union. They should be read in conjunction with the annual financial statements for the year ended 31 March 2020, which have been prepared in accordance with IFRS as adopted by the European Union. The accounting policies applied are consistent with those of the annual financial statements for the year ended 31 March 2020, as described in those annual financial statements. Where new standards or amendments to existing standards have become effective during the year, there has been no material impact on the net assets or results of the Group. The comparative results have been restated for the adoption of IFRS 16 (see note 8 for further details).

These interim financial statements have been prepared on a going concern basis using similar assumptions to those made in the statutory accounts to 31 March 2020.

Certain statements within this report are forward looking. The expectations reflected in these statements are considered reasonable. However, no assurance can be given that they are correct. As these statements involve risks and uncertainties the actual results may differ materially from those expressed or implied by these statements.

The interim financial statements have not been audited.

2. Segmental information

 

 

Central

Graphene and Plastic

Products

Metallic and Hard Wear

Products

Intra-group

Adjustments

 TOTAL

 

£'000

£'000

£'000

£'000

£'000

Six months to 30 September 2020

 

 

 

 

 

Sales

-

1,692

1,425

-

3,117

Gross Margin

-

295

215

-

510

Other gains/(losses)

(1,817)

-

-

-

(1,817)

Other operating income

-

70

4

-

74

Operating expenses

(1,191)

(1,443)

(399)

(9)

(3,042)

(Loss)/ profit from operations

(3,008)

(1,078)

(180)

(9)

(4,275)

Finance income/(charge)

(4)

(36)

(24)

-

(64)

(Loss)/profit before tax

(3,012)

(1,114)

(204)

(9)

(4,339)

 

 

 

 

 

 

 

2. Segmental information (continued)

 

 

 

 

Central

Graphene and Plastic

Products

Metallic and Hard Wear

Products

Intra-group

Adjustments

 TOTAL

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

Sales

-

1,854

2,522

-

4,376

Gross Margin

-

389

830

-

1,219

Other operating income

-

-

3

-

3

Operating expenses

(987)

(1,748)

(554)

7

(3,282)

(Loss)/profit from operations

(987)

(1,359)

279

7

(2,060)

Finance income/(charge)

1

(49)

(29)

-

(77)

(Loss)/ profit before tax

(986)

(1,408)

250

7

(2,137)

 

 

 

 

 

 

 

* The prior period results have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases', see note 8 for further information  

 

3. Exceptional items

 

 

Six months ended

30 September

2020

Unaudited

£'000

Six months ended

30 September

2019

Unaudited

£'000

Relocation and restructuring costs

 

6

17

Costs relating to expansion in China

 

70

220

Costs relating to setting up of the US subsidiary

 

-

67

Costs relating to setting up of the Korean subsidiary

 

6

-

Costs relating to asset purchase from Hanwha

 

85

-

Other

 

11

23

 

 

178

327

 

4. Taxation

The tax charge on the results for the period has been estimated at £nil (2019: £nil). At the last year end the Group had £14.7 million of trading losses carried forward to set-off against future trading profits.

 

5. Loss per share

The loss per share has been calculated by dividing the loss after taxation of £4,158,000 (2019: £1,878,000) by the weighted average number of shares in issue of 169,682,290 (2019: 153,894,000) during the period.

 

The calculation of the diluted earnings per share is based on the basic earnings per share adjusted to allow for the issue of shares on the assumed conversion of all dilutive options. However, in accordance with IAS33 "Earnings per Share", potential Ordinary shares are only considered dilutive when their conversion would decrease the profit per share or increase the loss per share. As at 30 September 2020 there were 14,677,130 (2019: 14,677,130) potential Ordinary shares that have been disregarded in the calculation of diluted earnings per share as they were considered non-dilutive at that date.

 

6. Intangible assets

 

30 September

2020

Unaudited

£'000

31 March

2020

Audited

£'000

Goodwill

3,555

3,555

Customer relationships/order books

41

54

Development costs

1,028

901

Licence

14

28

Intellectual property

204

182

Total

4,842

4,720

 

7. Dividends

As stated in the 2013 AIM Admission document the Board's objective is to continue to grow the Group's business and it is expected that any surplus cash resources will, in the short to medium term, be re-invested into the research and development of the Group's products. In view of this, no dividend is declared and the Directors will not be recommending a dividend for the foreseeable future. However, the Board intends that the Company will recommend or declare dividends at some future date once they consider it commercially prudent for the Company to do so, bearing in mind its financial position and the capital resources required for its development.

 

8. Restatements to the prior period

The income statement and the statement of cash flow for the six months to 30 September 2019 have been restated due to the recognition of Right of Use Assets as a result of the adoption of IFRS 16 'Leases'. This reinstatement has impacted the following items:

 

 

 

 

During 6 month period £'000

Operating expenses :

Operating lease rentals

 

329

Depreciation

(300)

 

29

Finance charges :

 

Impact of IFRS 16 lease interest

(45)

 

 

Total

(16)

 

 

Reconciliation of profit and loss for the six month period ended 30 September 2019:

 

 

As previously stated

£'000

Restatements

 

 

£'000

Restated

 

 

£'000

Continuing operations

 

 

 

Revenue

4,376

-

4,376

Cost of sales

(3,157)

-

(3,157)

Gross profit

1,219

-

1,219

Other operating income

3

-

3

Operating expenses (including exceptional items)

(3,311)

29

(3,282)

Loss from operations before exceptional items

(1,762)

29

(1,733)

Exceptional items

(327)

-

(327)

Loss from operations

(2,089)

29

(2,060)

Finance charge

(32)

(45)

(77)

Loss before income tax

(2,121)

(16)

(2,137)

Income tax

-

-

-

Loss for the period

(2,121)

(16)

(2,137)

 

 

Reconciliation of statement of cash flows as at 30 September 2019:

 

As previously stated

Restatements

Restated

Cash flows from operating activities

 

 

 

Cash used in operations

(1,093)

329

(764)

Interest paid

(32)

(45)

(77)

Net cash used in operating activities

(1,125)

284

(841)

Cash flows from investing activities

 

 

 

Purchase of intangible assets

(165)

-

(165)

Purchase of property, plant and equipment

(126)

-

(126)

Net cash used in investing activities

(291)

-

(291)

Cash flows from financing activities

 

 

 

Share issue

123

-

123

Finance leases net of repayments

(172)

172

-

Principal payment of leases under IFRS 16

-

(456)

(456)

Invoice discounting advances

(187)

-

(187)

Net cash generated from financing activities

(236)

(284)

(520)

Increase/(decrease) in cash and cash equivalents

(1,652)

-

(1,652)

Cash and cash equivalents at start of period

4,292

-

4,292

Cash and cash equivalents at end of period

2,640

-

2,640

 

 

As previously stated

Restatements

Restated

Loss before income tax

(2,121)

(16)

(2,137)

Adjustments for:

 

 

 

Share-based payments

596

-

596

Depreciation and amortisation

264

300

564

Finance cost

32

45

77

Increase in inventories

(7)

-

(7)

Decrease in trade and other receivables

125

-

125

Increase/(decrease) in trade and other payables

18

-

18

Cash used in operations

(1,093)

329

(764)

 

9. Post Balance Sheet Events

 

On 22 December 2020 the Company acquired certain graphene production related assets and intellectual property from South Korea based Hanwha Aerospace Company Limited for consideration comprising 11,000,000 ordinary shares of 1 pence each in the Company. The consideration is equivalent to 4.34 million at the 39.475 pence per Ordinary Share closing mid-market price on 18 December 2020.

 

10. Interim Report

 

This interim announcement is available on the Group's website at www.versarien.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR PPUAGGUPGPGU

Companies

Versarien (VRS)
UK 100

Latest directors dealings